精神医学65巻4号

2023年04月発行

特集 わが国の若手による統合失調症研究最前線

統合失調症の薬物治療ガイドラインとその普及・教育・検証活動

著者： 越智紳一郎¹ 橋本亮太²

所属機関： ¹愛媛大学大学院医学系研究科精神神経科学 ²国立精神・神経医療研究センター精神保健研究所精神疾患病態研究部

ページ範囲：P.463 - P.471

抄録
　本邦においても，日本神経精神薬理学会より，統合失調症の薬物治療ガイドラインが作成され，2022年には改訂版も上梓された。しかし，ガイドラインは，いまだ十分に利用されていないため，その普及と教育が必要である。精神科医療の普及と教育に対するガイドラインの効果に関する研究（EGUIDE）は，統合失調症薬物治療ガイドラインに関する講習を行い，ガイドラインの理解度，実践度，実際の処方行動をもとに，普及と教育と検証を行っている。さらにこれらのフィードバックによって講習内容や資料を適宜見直すことでよりよい講習ができるようにしている。また，ガイドラインの普及が進むことを検証するために実際の処方行動の調査研究や，ガイドラインをより利用しやすくするために，実際の処方がガイドラインの推奨内容にどれだけ適合しているかの適合度も作成することなどで，社会実装研究として患者のQOLの向上に寄与することを目指している。

参考文献

1）Barnes TR, Drake R, Paton C, et al：Evidence-based guidelines for the pharmacological treatment of schizophrenia：Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 34：3-78, 2020

2）Keepers GA, Fochtmann LJ, Anzia JM, et al：The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 177：868-872, 2020

3）Remington G, Addington D, Honer W, et al：Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry 62：604-616, 2017

4）Japanese Society of Neuropsychopharmacology：Japanese Society of Neuropsychopharmacology：“Guideline for Pharmacological Therapy of Schizophrenia. ” Neuropsychopharmacol Rep 41：266-324, 2021

5）Ichihashi K, Hori H, Hasegawa N, et al：Prescription patterns in patients with schizophrenia in Japan：First-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment（EGUIDE）” project. Neuropsychopharmacol Rep 40：281-286, 2020

6）Yang SY, Chen LY, Najoan E, et al：Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries：Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin Neurosci 72：572-579, 2018

7）Minds診療ガイドライン作成マニュアル編集委員会：Minds診療ガイドライン作成マニュアル2020 ver. 3.0．日本医療機能評価機構EBM医療情報部，2021　https://minds.jcqhc.or.jp/s/manual_2020_3_0［2023年1月10日閲覧］

8）Numata S, Nakataki M, Hasegawa N, et al：Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep 41：199-206, 2021

9）Takaesu Y, Watanabe K, Numata S, et al：Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment（EGUIDE）' project：A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci 73：642-648, 2019

10）Yamada H, Motoyama M, Hasegawa N, et al：A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders：the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment（EGUIDE）project. BJPsych Open 8：e83, 2022

11）Ogasawara K, Numata S, Hasegawa N, et al：Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep 42：221-225, 2022

12）Iida H, Okada T, Nemoto K, et al：Satisfaction with web-based courses on clinical practice guidelines for psychiatrists：Findings from the “Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment（EGUIDE）” project. Neuropsychopharmacol Rep 43：23-32, 2023

13）Hashimoto N, Yasui-Furukori N, Hasegawa N, et al：Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder：Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education（EGUIDE）psychiatric treatment project. Asian J Psychiatr 63：102744, 2021

14）Furihata R, Otsuki R, Hasegawa N, et al：Hypotic medication use among inpatients with schizophrenia and major depressive disorder：results of a nationwide study. Sleep Med 89：23-30, 2022

15）Hori H, Yasui-Furukori N, Hasegawa N, et al：Prescription of Anticholinergic Drugs in Patients With Schizophrenia：Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. Front Psychiatry 13：823826, 2022

16）Ichihashi K, Kyou Y, Hasegawa N, et al：The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder：A nationwide survey from the EGUIDE project. Asian J Psychiatr 69：103007, 2022

17）Kyou Y, Yasui-Furukori N, Hasegawa N, et al：The characteristics of discharge prescriptions including psychotropic pro re nata in patients for schizophrenia and major depressive disorder from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment（EGUIDE）” project. Ann Gen Psychiatry 21：52, 2022

18）Muraoka H, Kodaka F, Hasegawa N, et al：Characteristics of the treatments for each severity of major depressive disorder：A real-world multi-site study. Asian J Psychiatr 74：103174, 2022

19）Okada T, Hori H, Hasegawa N, et al：Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. J Clin Psychopharmacol 42：591-593, 2022

20）Ochi S, Tagata H, Hasegawa N, et al：Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics：A real-world nationwide study. Int J Neuropsychopharmacol 25：818-826, 2022

21）Tsuboi T, Takaesu Y, Hasegawa N, et al：Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications：a propensity score-matched analysis. Psychiatry Clin Neurosci 77：30-37, 2023

22）Yasui-Furukori N, Muraoka H, Hasegawa N, et al：Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep 42：3-9, 2022

23）Inada K, Fukumoto K, Hasegawa N, et al：Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia. ” Neuropsychopharmacol Rep 42：502-509, 2022

24）Fukumoto K, Kodaka F, Hasegawa N, et al：Development of an individual fitness score（IFS）based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep 43：33-39, 2023